COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean

Virtual Health Sciences Library

  • Home
  • Search
  • Knowledge Base
  • Get a journal indexed in the Index Medicus
  • MyVHSL
  1. Home
  2. IMEMR
  3. Search Result
  4. Determination of cefdinir in human plasma using HPLC coupled withtandem mass spectroscopy: application to bioequivalence studies

Determination of cefdinir in human plasma using HPLC coupled withtandem mass spectroscopy: application to bioequivalence studies

Authors

Tutunji Lara F.
University of Jordan ; , Faculty of Pharmacy ; , Department of Pharmaceutics and Pharmaceutical Sciences ;

Jordan Med. J. 2015; 8 (2): 123-139
Jordan Journal of Pharmaceutical Sciences
Journal Country: Jordan
P-ISSN: 1995-7157
Indexing Status : In Process
Citation: Lara F. Tutunji , Determination of cefdinir in human plasma using HPLC coupled withtandem mass spectroscopy: application to bioequivalence studies, Jordan Med. J. 2015; 8 (2): 123-139

Abstract English

A sensitive and selective liquid chromatographic method coupled with tandem mass spectrometry has been developedand validated for the determination of cefdinir in human plasma. The analytes cefdinir and cephalexin [internalstandard] were separated on a reversed phase column [Merck, Purospher RP-C18, 30 X 4.6 [mm] , 3 micro m] using a mobilephase consisting of an aqueous solution of formic acid in water [0.10 %] and acetonitrile [85: 15 v/v [%] , flow rate0.50 [mL/min.] . Detection utilized a tandem MS/MS, the analytes were ionized using an ESI source in the positive ionmode prior to detection and analysis using Multiple Reaction Monitoring mode [MRM] . The analytes were monitoredat the following transitions [m/z] 396.10 [right arrow] 226.90, and [m/z] 348.24 [right arrow] 158.10 for cefdinir and cephalexinrespectively. Cefdinir linearity was demonstrated over the concentrations ranging from 10 to 1200 [ng/ mL] . Thedeveloped method was fully validated prior to its application on a bioequivalence study involving cefdinir [125 mg/5ml] suspension in healthy volunteers [N= 26] under fasting conditions

Full Text English

Subscribe to VHSL Newsletters

© 2020 WHO – EMRO